1.
Pediatr Blood Cancer
; 68(12): e29346, 2021 12.
Article
in English
| MEDLINE
| ID: mdl-34569142
ABSTRACT
Cutaneous adverse events (cAEs) from targeted antineoplastic agents and immune checkpoint inhibitors are common in children with cancer and may lead to dose reduction or cessation of critical oncologic treatment. Timely diagnosis and proper management of cAEs in pediatric oncology patients is essential to optimize ongoing cancer-directed therapy and improve quality of life. This systematic review of published studies summarizes dermatologic toxicities to targeted anticancer treatments and immune checkpoint inhibitors.
Subject(s)
Antineoplastic Agents , Neoplasms , Antineoplastic Agents/adverse effects , Child , Humans , Immune Checkpoint Inhibitors , Immunotherapy/adverse effects , Neoplasms/drug therapy , Neoplasms/etiology , Quality of Life , Skin
2.